These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12534006)

  • 1. [Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
    MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534006
    [No Abstract]   [Full Text] [Related]  

  • 2. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 3. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR
    Nutr Metab Cardiovasc Dis; 2006 Dec; 16(8):509-12. PubMed ID: 17071064
    [No Abstract]   [Full Text] [Related]  

  • 4. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS
    Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FIELD study.
    Rees A
    Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination statin-fibrate therapy: safety aspects.
    Franssen R; Vergeer M; Stroes ES; Kastelein JJ
    Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
    Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Normalization of blood pressure and lipids in patients with diabetes].
    Clemens A; Gallwitz B
    Med Klin (Munich); 2003 Jul; 98(7):368-76. PubMed ID: 12937902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 12. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
    Tahrani AA
    Int J Clin Pract; 2006 Nov; 60(11):1515; author reply 1515-6. PubMed ID: 17073848
    [No Abstract]   [Full Text] [Related]  

  • 13. Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits.
    Cardiovasc J Afr; 2007; 18(6):400. PubMed ID: 18092120
    [No Abstract]   [Full Text] [Related]  

  • 14. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
    Karalliedde J; Viberti GC
    Diabetes; 2007 May; 56(5):e3; author reply e4. PubMed ID: 17470560
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 18. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B
    Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
    Allemann S; Diem P; Egger M; Christ ER; Stettler C
    Curr Med Res Opin; 2006 Mar; 22(3):617-23. PubMed ID: 16574044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.